Publicaciones en colaboración con investigadores/as de University of Amsterdam (10)

2024

  1. Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care

    The Journal of rheumatology, Vol. 51, Núm. 4, pp. 378-389

2022

  1. European bio-naïve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response

    Rheumatology (Oxford, England), Vol. 61, Núm. 9, pp. 3799-3807

  2. Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries

    Arthritis Care and Research, Vol. 74, Núm. 7, pp. 1205-1218

2016

  1. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force

    Annals of the Rheumatic Diseases, Vol. 75, Núm. 1, pp. 3-15

2015

  1. Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study

    PLoS Medicine, Vol. 12, Núm. 3

  2. Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology

    Annals of the Rheumatic Diseases, Vol. 74, Núm. 6, pp. 963-969

2014

  1. Multinational evidence-based recommendations for the diagnosis and management of gout: Integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative

    Annals of the Rheumatic Diseases, Vol. 73, Núm. 2, pp. 328-335

2012

  1. Safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of the monoclonal antibody ASK8007 blocking osteopontin in patients with rheumatoid arthritis: A randomised, placebo controlled, proof-of-concept study

    Annals of the Rheumatic Diseases, Vol. 71, Núm. 2, pp. 180-185

2010

  1. CCR5 blockade in rheumatoid arthritis: A randomised, double-blind, placebo-controlled clinical trial

    Annals of the Rheumatic Diseases, Vol. 69, Núm. 11, pp. 2013-2016

  2. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis

    Science Translational Medicine, Vol. 2, Núm. 52